Insight

Bishal Gyawali: Here is a list of our top 10 publications from 2023

Photo of Bishal Gyawali taken from qcri.queensu.ca

Jan 6, 2024, 12:09

Bishal Gyawali: Here is a list of our top 10 publications from 2023

Bishal Gyawali, Medical Oncologist and Assistant Professor at Queen’s University, shared on X:

“Happy New Year 2024. If you’re looking for some year-end reading, here is a list of our top 10 publications from 2023:

1. CSO (Common Sense Oncology) manifesto, The Lancet Oncology.

2. Accelerated Approval Program for Cancer Drugs, NEJM.

3. HTA Assessment for cancer drugs across high-income countries, The Lancet Oncology.

4. Problematic crossovers in cancer drug trials, Nature Reviews Clinical Oncology.

5. Relation between price and clinical benefit of cancer drugs in Canada, JAMA Network Open.

6. Immunotherapy in pre-patients, JAMA Oncology.

7. PFS as the primary endpoint for registration trials, Journal of Clinical Oncology.

8. How to evaluate adjuvant therapy trials? Journal of Clinical Oncology.

9. On informative censoring in the context of MonarchE trial, The Lancet Oncology.

10. Role of colonoscopy screening in the context of the NordICC trial: is it the trial or the procedure that failed? eClinicalMedicine – The Lancet Discovery Science.

This has been an amazing year but wouldn’t have been possible without teamwork and support both at work and at home. Huge thanks to all my coauthors, students, mentees, colleagues, collaborators, mentors, patients and advocates, reviewers, and editors for helping us publish these papers that can hopefully move the needle in the right direction for better patient-centric care.”

Source: Bishal Gyawali/X

Accelerated Approval Program Bishal Gyawali cancer CSO manifesto How to evaluate adjuvant therapy trials HTA Assessment immunotherapy JAMA Network Open Journal of Clinical Oncology Nature Reviews Clinical Oncology NEJM NordICC trial OncoDaily Oncology price and clinical benefit of cancer drugs in Canada Problematic crossovers Role of colonoscopy screening The Lancet Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage